Cancer Family
Cutaneous Melanocytic Neoplasm
CI-CAN-00000154Explore in graph →
Non-malignant81 active trials1 approved drugs61 evidence items
- NCIt
- C7161
Loading cancer entity…
Cancer Family
CI-CAN-00000154Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07068074 | Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma | recruiting | Phase 3 | 428 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT01274338 | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,673 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 |
| clinicaltrials |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | active not recruiting | Phase 2 / Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,301 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | recruiting | Phase 2 / Phase 3 | 135 | Linnaeus Therapeutics, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | recruiting | Phase 3 | 140 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials